Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

International Journal of Clinical Practice
S PrasadS E Libretto


Economic evaluation of healthcare technologies is becoming increasingly relevant, enabling decision makers to assess and compare treatments within the context of costs and outcomes. Moreover, it is increasingly important for clinicians and prescribers to have some understanding of economic evaluation. For attention-deficit/hyperactivity disorder (ADHD), economic evaluations have largely focused on pharmacotherapy, and results indicate that such treatments are cost-effective compared with other interventions. This review provides an overview of ADHD, its consequences and pharmacotherapy; describes the principles of health economic analysis, health-related quality of life (HRQL) and a cost-effectiveness model of atomoxetine for ADHD treatment; and outlines guidance from the National Institute for Health and Clinical Excellence on ADHD pharmacotherapy. The cost-effectiveness of atomoxetine for children with ADHD in the UK was compared with treatment alternatives using an economic model with Markov processes. The model evaluated atomoxetine in five patient subgroups according to treatment history and comorbidities precluding stimulants. Incremental cost per quality-adjusted life-year (QALY) was calculated and compared between treat...Continue Reading


Jun 1, 1985·The American Journal of Medicine·J J GordonJ P Phair
Aug 1, 1995·Journal of Clinical Psychopharmacology·T E WilensJ Prince
Mar 1, 1996·Journal of the American Academy of Child and Adolescent Psychiatry·S R PliszkaJ W Maas
Apr 1, 1996·Journal of the American Academy of Child and Adolescent Psychiatry·T SpencerS Griffin
Jan 1, 1997·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·E Tom, K A Schulman
May 1, 1997·Health Economics·M J BuxtonM Vray
May 7, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·L L GreenhillH Abikoff
May 5, 2000·European Child & Adolescent Psychiatry·M DanckaertsE Taylor
Apr 25, 2002·Emergency Medicine Journal : EMJ·S Goodacre, C McCabe
Dec 17, 2002·Journal of Glaucoma·Gisela Kobelt
Dec 9, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stan KutcherSam Tyano
Apr 13, 2004·Medical Care·Anne W RileyBert F Green
Jun 15, 2004·Journal of Developmental and Behavioral Pediatrics : JDBP·Louis S MatzaChristopher J Kratochvil
Jun 24, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·David MichelsonJoseph Biederman
Aug 17, 2004·Journal of Developmental and Behavioral Pediatrics : JDBP·Amy R PerwienAlbert J Allen
Sep 2, 2004·Pharmacotherapy·Alisa K ChristmanJohn S Markowitz
Sep 15, 2004·European Child & Adolescent Psychiatry·Jan K BuitelaarUNKNOWN Stomoxetine International Study Group
Jan 28, 2005·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Kristina SecnikSally Mannix
Mar 23, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·Rhonda MartinussenRosemary Tannock
Jun 11, 2005·Cost Effectiveness and Resource Allocation : C/E·Louis S MatzaManishi Prasad
May 6, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·N K LeidyB Genesté
May 9, 2006·European Child & Adolescent Psychiatry·Tobias BanaschewskiEric Taylor
Jul 25, 2006·The Journal of Pediatrics·Timothy E WilensLouise R Levine
Jul 26, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Christopher J KratochvilDouglas L Gelowitz
Aug 19, 2007·Journal of Developmental and Behavioral Pediatrics : JDBP·William J BarbaresiSteven J Jacobsen
Jan 8, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Mark E BangsAlbert J Allen
Mar 28, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Mark E BangsJoachim F Wernicke
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Suzi CottrellKristina S Boye
Jun 11, 2008·Clinical Child Psychology and Psychiatry·Michael TettenbornUNKNOWN ADORE UK Study Group

❮ Previous
Next ❯


Nov 15, 2011·Academic Pediatrics·S Maria E FinnellStephen M Downs
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Nick AdlardEmma Frew
Apr 2, 2013·Journal of Obstetrics and Gynaecology of India·Deepti ShrivastavaAmreen Singh
Aug 19, 2015·The American Journal of Tropical Medicine and Hygiene·Don P MathangaSimon J Brooker
Aug 28, 2015·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C BritesS M Ciasca
Jan 20, 2019·Tropical Medicine & International Health : TM & IH·Dominik GeusFrank P Mockenhaupt
Feb 11, 2014·Public Health Nutrition·Abdul Razak NurliyanaAbdullah Rohani
Feb 5, 2019·Pediatric Diabetes·Marko SimunovicVeselin Skrabic
Mar 2, 2011·Public Health Nutrition·Elizabeth W Kimani-MurageShane A Norris
Apr 17, 2012·Pediatric Obesity·O AndroutsosC Kanaka-Gantenbein
Aug 2, 2018·Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo·Mariana de Santis FilgueirasJuliana Farias de Novaes
May 28, 2016·British Journal of Nursing : BJN·Heather Membride
Nov 26, 2019·Pediatric Pulmonology·Nagehan EmiralioğluUğur Özçelik
May 4, 2017·Health and Quality of Life Outcomes·Miguel A Cruz-FelicianoIbis S Carrión-González
Nov 14, 2017·The Medical Journal of Australia·Matthew P HamiltonPatrick D McGorry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Milton C WeinsteinAlistair McGuire
© 2022 Meta ULC. All rights reserved